Hot Features
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for... Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -1.13636363636 | 0.44 | 0.475 | 0.41 | 112860 | 0.43839091 | CS |
| 4 | -0.215 | -33.0769230769 | 0.65 | 0.74 | 0.41 | 149132 | 0.50252396 | CS |
| 12 | -0.335 | -43.5064935065 | 0.77 | 0.79 | 0.41 | 113638 | 0.57451585 | CS |
| 26 | -1.165 | -72.8125 | 1.6 | 1.78 | 0.41 | 125821 | 0.82256527 | CS |
| 52 | -0.475 | -52.1978021978 | 0.91 | 1.97 | 0.41 | 90945 | 0.96634581 | CS |
| 156 | -0.365 | -45.625 | 0.8 | 2.98 | 0.215 | 82636 | 1.26758779 | CS |
| 260 | -4.345 | -90.89958159 | 4.78 | 4.8 | 0.215 | 68003 | 1.46717974 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.